在黑色素瘤中,Toll-like受体信号通路的分子特征和治疗含义
Hewen Guan1, Xu Chen2, Jifeng Liu2
1Department of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Scientific reports
|September 4, 2023
概括
这项研究揭示了托尔类受体 (TLR) 基因对黑色素瘤至关重要. 使用六个TLR基因的新预后模型准确预测黑色素瘤患者的生存率和免疫特征.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 黑色素瘤是一种黑色素细胞的癌症,通常具有免疫性,但Toll-like受体 (TLR) 的作用尚不清楚.
- 在不同癌症中,TLR基因表达有所不同,受瘤免疫微环境的影响.
研究的目的:
- 为了研究TLR相关基因在黑色素瘤中的作用.
- 开发基于TLR基因表达的黑色素瘤预后模型.
- 在黑色素瘤中探索TLR途径,预后,免疫透和代谢重编程之间的相关性.
主要方法:
- 使用TCGA和GEO数据对TLR基因变异 (CNV,SNV,mRNA) 的泛癌分析.
- 基于TLR通路表达的黑色素瘤患者的集群.
- 使用考克斯回归和LASSO分析构建和验证六基因预后模型.
主要成果:
- 黑色素瘤患者根据TLR途径表达被分为三个子组.
- 这项研究确定了TLR途径与黑色素瘤预后,免疫透,代谢重编程和癌基因表达之间的显著相关性.
- 开发了一种有效的预后模型,包括六个TLR相关基因.
结论:
- 基于TLR相关基因的新型预后生存模型准确评估黑色素瘤患者的预后和免疫特征.
- 这个模型具有改善患者生存结果的关键潜力.
- 了解TLRs的作用对于黑色素瘤治疗策略至关重要.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


